Kiniksa Pharmaceuticals International, plc (KNSA)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Kiniksa Pharmaceuticals International, plc (KNSA) Upgraded to Strong Buy: Here's What You Should Know
Kiniksa Pharmaceuticals International, plc (KNSA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Kiniksa Pharmaceuticals International, plc (KNSA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Kiniksa Pharmaceuticals International, plc (KNSA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Kiniksa: Increased Outlook For Arcalyst, Augmented By Pipeline Maturation
Kiniksa Pharmaceuticals continues to outperform, with Arcalyst net sales poised to surpass my previous bullish estimates. Arcalyst captured 18% of the recurrent pericarditis market by end-2025, with average therapy duration rising to three years and further upside from a new consumer awareness campaign. KPL-387, a next-generation IL-1 antibody, is set for phase 2 proof-of-concept data in H2 2026, offering improved economics and patient convenience compared to Arcalyst.
Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2026 Earnings Call Transcript
Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2026 Earnings Call Transcript
Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.11 per share a year ago.
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2025 Earnings Call Transcript
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2025 Earnings Call Transcript
Kiniksa Pharmaceuticals International, plc (KNSA) Misses Q4 Earnings Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.29 per share. This compares to a loss of $0.12 per share a year ago.
Kiniksa Pharmaceuticals International, plc (KNSA) Earnings Expected to Grow: Should You Buy?
Kiniksa Pharmaceuticals International, plc (KNSA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kiniksa: Arcalyst Is The Engine, But KPL-387 Is The Accelerator
Kiniksa transitions from survival risk to growth, targeting dominance in the pericarditis market with robust cash flow and expanding margins. KNSA's Arcalyst drives revenue growth, with 2026 guidance of $900–$920 million, approaching blockbuster status and supporting self-funding operations. Pipeline evolution with KPL-387 aims to improve adherence, capture full economics, and expand the addressable market, with Phase 2 data in H2 2026 as a key catalyst.
Kiniksa Pharmaceuticals International, plc (KNSA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Kiniksa Pharmaceuticals International, plc (KNSA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Kiniksa: How Category Ownership And Higher Duration Are Translating Into Operating Leverage
Kiniksa Pharmaceuticals leverages ARCALYST as it is a first-in-class FDA-approved treatment for recurrent pericarditis, driving recurring revenue and strong growth. Q3 FY2025 ARCALYST revenue was $180.9M (+61% YoY, +15% QoQ), prompting raised FY2025 guidance to $670–$675M. ARCALYST's efficacy and new ACC guidance support increased patient-months, leading to a more steady revenue stream and reposition users for longer-term use.
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings Miss Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.23 per share, missing the Zacks Consensus Estimate of $0.33 per share. This compares to a loss of $0.18 per share a year ago.
